Heron Therapeutics (HRTX) EBITDA Margin (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly EBITDA Margin came in at 5.43% in Q2 2026, down 103.0% on a YoY basis from 180.89% in Q2 2025, and up 60.47% quarter-over-quarter from 13.73% in Q1 2026.
Powered by 
Analysis
Heron Therapeutics (HRTX) EBITDA Margin (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has reported EBITDA Margin for 12 consecutive years, with 5.43% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin fell 103.0% year-over-year to 5.43%; the trailing twelve-month figure through Jun 2026 stood at 7.19% (down 801.0% YoY), and the FY2025 full-year result was 1.64%, up 635.0% from the prior year.
- EBITDA Margin advanced to 5.43% in Q2 2026 per HRTX's latest filing, from 13.73% in the prior quarter.
- Across five years, EBITDA Margin topped out at 10.23% in Q4 2024 and bottomed at 268.25% in Q1 2022.
- Historically, EBITDA Margin has averaged 60.46% across 5 years, with a median of 15.86% in 2024.
- The sharpest annual moves came in 2022 and 2026: EBITDA Margin soared 19141 bps in 2022, then plunged 2183 bps in 2026.
- Over 5 years, EBITDA Margin stood at 67.79% in 2022, then surged by 56 bps to 29.85% in 2023, then jumped by 134 bps to 10.23% in 2024, then slumped by 99 bps to 0.09% in 2025, then tumbled by 5896 bps to 5.43% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 5.43%, 13.73%, and 0.09% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -23.56% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -0.36% |
| 10 | Heron Therapeutics | 64.55 Mn | 21.89 Mn | 26.09 Mn | -5.43% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5.43% |
| Mar 31, 2026 | -13.73% |
| Dec 31, 2025 | 0.09% |
| Sep 30, 2025 | -10.71% |
| Jun 30, 2025 | -4.40% |
| Mar 31, 2025 | 8.11% |
| Dec 31, 2024 | 10.23% |
| Sep 30, 2024 | -13.59% |
| Jun 30, 2024 | -17.89% |
| Mar 31, 2024 | -13.84% |
| Dec 31, 2023 | -29.85% |
| Sep 30, 2023 | -79.31% |
| Jun 30, 2023 | -133.50% |
| Mar 31, 2023 | -111.64% |
| Dec 31, 2022 | -67.79% |
| Sep 30, 2022 | -157.71% |
| Jun 30, 2022 | -179.15% |
| Mar 31, 2022 | -268.25% |
| Dec 31, 2021 | -259.20% |
| Sep 30, 2021 | -222.59% |